Clinical trials: Vision Therapy
Dry Eye Disease
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01276223
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Where
- United States
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Amblyopia
Levodopa for the Treatment of Residual Amblyopia
The purpose of this study is to evaluate the efficacy and safety of oral levodopa and patching versus oral placebo and patching as treatment for residual amblyopia in children 7 to <13 years old with visual acuity of 20/50 to…
- Trial name
- ATS17 (NCT01190813)
- Testing
- Levodopa/Carbidopa, Patching
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Jaeb Center for Health Research
Ocular Hypertension, Open Angle Glaucoma
Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)
To evaluate if preservative free cosopt is well tolerated in patients with Open angle glaucoma (OAG) or Ocular hypertension (OH) with dry eyes.
- Trial name
- DISCOVER (NCT00545064)
- Testing
- dorzolamide hydrochloride (+) timolol maleate
- Volunteers
- 176 people
- Sponsor
- Merck Sharp & Dohme LLC
Seasonal Allergic Conjunctivitis
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal…
- Trial name
- NCT01435460
- Testing
- Loteprednol etabonate 0.2%, Olopatadine 0.1%
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Bausch & Lomb Incorporated
Myopia
Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment
The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of the NeuroVision Low Myopia Treatment. The specific questions to be answered are: 1.
- Trial name
- NCT00469612
- Testing
- NeuroVision's NVC treatment for Low Myopia
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Glioblastoma Multiforme
UNITE Study: Understanding New Interventions With GBM ThErapy
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor…
- Trial name
- NCT03419403
- Testing
- Steroid eye drops, Vasoconstrictor eye drops, Cold compress
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Glaucoma
How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
- Trial name
- NCT00798694
- Testing
- Xalatan, Travatan Z
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Wills Eye
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Amblyopia
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
This study is designed to evaluate the effectiveness of adding a plano lens to weekend atropine after visual acuity has stabilized with weekend atropine but amblyopia is still present.
- Trial name
- ATS16 (NCT00944710)
- Testing
- Atropine, Plano lens
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Jaeb Center for Health Research
Presbyopia, Refractive Error
Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
- Conditions
- Presbyopia, Refractive Error, Eye Diseases, Near Vision
- Trial name
- CLARITY 1 (NCT05656027)
- Testing
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine
- Where
- 25 sites in United States
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- LENZ Therapeutics, Inc
Glaucoma
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured…
- Trial name
- NCT02512042
- Testing
- Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
- Where
- 10 sites in United States
- Volunteers
- 973 people
- Sponsor
- Actavis Inc.
Age-Related Macular Degeneration, Choroidal Neovascularization
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
This study examined whether the anti-inflammatory medicines infliximab, sirolimus or daclizumab, when given with a participant's current therapies, would prevent the growth of new blood vessels in the eye in participants with…
- Trial name
- AMDB1 (NCT00304954)
- Testing
- Intravenous Daclizumab, Intravenous Infliximab, Observation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Eye Institute (NEI)
Inflammation Associated With Cataract Surgery
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
- Trial name
- NCT01606735
- Testing
- IBI-10090
- Where
- 2 sites in United States
- Volunteers
- 172 people
- Sponsor
- ICON Bioscience Inc
Dry Eye
IVIG-eye Drops Treatment for Dry Eye Disease
The main objective of this study is to establish whether patients with Dry Eye Disease are able to safely tolerate receiving Intravenous Immunoglobulin (IVIG) eye drops two times a day for eight weeks (primary 'safety and…
- Trial name
- NCT03992482
- Testing
- Intravenous Immune Globulin (IVIG)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sandeep Jain, MD
Meibomian Gland Dysfunction, Posterior Blepharitis
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
This is a Phase IV, single site, randomized, double masked, parallel control clinical trial of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for treatment of ocular surface inflammation due to…
- Trial name
- ZvL (NCT01456780)
- Testing
- Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Non-24-Hour Sleep-Wake Disorder
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01430754
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vanda Pharmaceuticals
Albinism, Vision Loss
Nitisinone for Type 1B Oculocutaneous Albinism
Background: Oculocutaneous albinism, type 1B (OCA1B) is a genetic disease caused by problems in the gene that makes tyrosine. Tyrosine is an amino acid needed to produce pigment in the skin, hair, and eyes.
- Trial name
- NCT01838655
- Testing
- Nitisinone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Achromatopsia
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
This is a longer-term follow-up study of patients with achromatopsia associated with defects in CNGA3 who participated in a clinical trial in which they received AAV-CNGA3 retinal gene therapy, or of patients with achromatopsia…
- Trial name
- NCT03278873
- Testing
- Prior exposure to AAV-CNGA3 or AAV-CNGB3
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- MeiraGTx UK II Ltd
Amblyopia
Regimens of Intermittent Occlusion Therapy for Amblyopia in Children
This study is designed to answer the question: What if the Intermittent Occlusion (IO-therapy) glasses were prescribed all day (12-hours) in which the total time of treatment only took 4 weeks instead of the current treatment…
- Trial name
- NCT02767856
- Testing
- IO-therapy Glasses
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Salus University